A potential solution to immunosuppression of the tumour microenvironment: results of a phase 1 clinical trial of anti-OX-40 in head and neck squamous cell carcinoma. (March 2017) - Leidner, R.; Crittenden, M.; Gough, M.; Fox, B.A.; Weinberg, A.D.; Dierks, E.J.; Bell, R.B.